NRx Pharmaceuticals, Inc. (NRXP)
NASDAQ: NRXP · Real-Time Price · USD
2.450
-0.220 (-8.24%)
At close: Nov 7, 2025, 4:00 PM EST
2.490
+0.040 (1.63%)
After-hours: Nov 7, 2025, 7:56 PM EST
NRx Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts that cover NRx Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $31.6, which forecasts a 1,189.80% increase in the stock price over the next year. The lowest target is $18 and the highest is $47.
Price Target: $31.6 (+1,189.80%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for NRx Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 5 | 5 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $46 → $47 | Strong Buy | Maintains | $46 → $47 | +1,818.37% | Oct 30, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $34 | Strong Buy | Maintains | $34 | +1,287.76% | Oct 21, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +1,532.65% | Oct 16, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +1,532.65% | Oct 1, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $34 | Strong Buy | Maintains | $34 | +1,287.76% | Sep 29, 2025 |
Financial Forecast
Revenue This Year
26.60M
Revenue Next Year
131.68M
from 26.60M
Increased by 395.09%
EPS This Year
-0.29
from -2.36
EPS Next Year
0.34
from -0.29
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 36.8M | 253.5M | |||
| Avg | 26.6M | 131.7M | |||
| Low | 17.2M | 41.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 853.0% | |||
| Avg | - | 395.1% | |||
| Low | - | 57.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.14 | 0.44 | |||
| Avg | -0.29 | 0.34 | |||
| Low | -0.56 | 0.25 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.